These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1903725)

  • 21. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
    Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of endogenous gonadotropin release in the etiology of ovarian enlargement during purified urinary follicle-stimulating hormone therapy.
    Mizunuma H; Takagi T; Yamada K; Andoh K; Ibuki Y; Igarashi M
    Fertil Steril; 1991 Jan; 55(1):66-72. PubMed ID: 1898893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination: A single center retrospective cohort study.
    Arya S; Kupesic-Plavsic S; Mulla ZD; Dwivedi AK; Crisp Z; Jose J; Noble LS
    Eur J Obstet Gynecol Reprod Biol; 2017 Nov; 218():123-128. PubMed ID: 28985546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase in androgen:estrogen ratio specifically during low-dose follicle-stimulating hormone therapy for polycystic ovary syndrome.
    Brzyski RG; Grow DR; Sims JA; Seltman HJ
    Fertil Steril; 1995 Oct; 64(4):693-7. PubMed ID: 7672136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical therapeutic effects of acupuncture combined with Chinese herbal medicine on infertility of polycystic ovary syndrome in the patients with ovulation induction with letrozole].
    Yin Y; Zhang Y; Zhang H; Jiang D; Guo G
    Zhongguo Zhen Jiu; 2018 Jan; 38(1):27-32. PubMed ID: 29354933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of total testosterone for pregnancy during treatment in patients with clomiphene-citrate-resistant polycystic ovary syndrome: a pilot study.
    Li C; Cheng J; Wang J; Xue Y; Huang Z; Zhang S; Lv J
    Arch Gynecol Obstet; 2011 Sep; 284(3):757-64. PubMed ID: 21614496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
    Marci R; Senn A; Dessole S; Chanson A; Loumaye E; De Grandi P; Germond M
    Fertil Steril; 2001 Jun; 75(6):1131-5. PubMed ID: 11384638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
    Saffan D; Seibel MM
    Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between follicle-stimulating hormone dose and level and its relevance for ovulation induction with adjuvant gonadotropin-releasing hormone-agonist treatment.
    Scheele F; Hompes PG; van der Meer M; Schoute E; Schoemaker J
    Fertil Steril; 1993 Oct; 60(4):620-5. PubMed ID: 8405514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.
    Laven JS; Mulders AG; Visser JA; Themmen AP; De Jong FH; Fauser BC
    J Clin Endocrinol Metab; 2004 Jan; 89(1):318-23. PubMed ID: 14715867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
    Papaleo E; Doldi N; De Santis L; Marelli G; Marsiglio E; Rofena S; Ferrari A
    Hum Reprod; 2001 Nov; 16(11):2263-6. PubMed ID: 11679501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The "regulating conception-governor vessel" acupuncture method for infertility of polycystic ovarian syndrome].
    Zhuo Y; Wu J; Lin W; Pi M; Chen P; Yang Z
    Zhongguo Zhen Jiu; 2016 Dec; 36(12):1237-1241. PubMed ID: 29231358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.